TacticScaleWhat Align Technology Does & How It Makes Money (ALGN)
Updated October 2026 · reflects Align Technology's latest reported financials
Maker of Invisalign clear aligners and iTero intraoral scanners. It earns most of its money selling Invisalign treatment packages and retainers to orthodontists and dentists.
How Align Technology makes money
It earns most of its money selling Invisalign treatment packages and retainers to orthodontists and dentists. It also sells or rents iTero scanners and charges for software subscriptions, disposables, pay-per-scan services, and exocad CAD/CAM software.
What Align Technology does
Align Technology is best known for Invisalign, a leading clear aligner brand for straightening teeth. Its Clear Aligner segment offers treatment packages for adults, teens, and children ages six to ten, plus lighter options for simpler cases (Express, Lite, Moderate, Go). It also sells Vivera retainers, whitening products, a 3D printed palatal expander, training, and accessories for dental professionals. The Imaging Systems and CAD/CAM Services segment is built around the iTero intraoral scanner, which dentists use for both orthodontic and restorative work. Related offerings include exocad design software, treatment simulation and progress tracking tools, and recurring revenue from subscriptions, scanner rentals, disposables, and pay-per-scan services. The scanners feed digital cases into the aligner business, so the two segments support each other. Founded in 1997, the company is headquartered in Tempe, Arizona.
Products & services
- Invisalign clear aligners
- Vivera retainers
- iTero intraoral scanners
- exocad CAD/CAM software
- Invisalign Palatal Expander
- Align Oral Health Suite
What is Align Technology worth?
On an owner-earnings DCF, Align Technology's most-likely value is about $221 versus a recent price near $143 (55% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$107) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Envista (NVST) · Integra LifeSciences (IART) · DENTSPLY SIRONA (XRAY) · Double Medical Technology (002901.SZ)